Clinical trials: VITILIGO
Non-Segmental Vitiligo
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo
This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
- Trial name
- NCT07828639
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Vitiligo
Janus Kinase 1 in Vitiligo & Psoriasis
Assessment of the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases.
- Trial name
- NCT03762551
- Testing
- skin biopsy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cairo University
Vitiligo, Pediatric ALL
Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children
Vitiligo is a auto immune that impact 2% of the global population, regardless from the phototype. Even though it affects patients in a physical way through loss of pigmentation, it is also impacting them on a mental/emotional…
- Conditions
- Vitiligo, Pediatric ALL, Dermatologic Disease, Autoimmune Diseases
- Trial name
- NCT06035614
- Testing
- exciplex, Tacrolimus ointment
- Where
- Jordan
- Volunteers
- 50 people
- Sponsor
- Clarteis
Vitiligo
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- Viti-Up (NCT06118411)
- Testing
- Upadacitinib, NB-UVB (narrow-band ultraviolet B) Phototherapy
- Where
- 148 sites in United States, Argentina and 17 more
- Volunteers
- 614 people
- Sponsor
- AbbVie
Non Segmental Vitiligo
ICP-332 in Subjects With Non-segmental Vitiligo
This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an…
- Trial name
- NCT07047612
- Testing
- ICP-332 Tablets
- Where
- 45 sites in China
- Volunteers
- 603 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Alopecia Areata, Alopecia Totalis
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Alopecia Areata (& Ophiasis)
- Trial name
- NCT05098600
- Testing
- Exposure of interest
- Where
- Czechia
- Volunteers
- 123 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Vitiligo
Plasma Exeresis Plus NB-UVB Versus NB-UVB Alone for Stable Vitiligo
The goal of this quasi-experimental clinical trial is to compare the effectiveness of plasma exeresis combined with narrowband ultraviolet B (NB-UVB) phototherapy versus NB-UVB monotherapy in patients with stable non-segmental…
- Trial name
- NCT07907744
- Testing
- Plasma Exeresis, Narrowband Ultraviolet B (NB-UVB) Phototherapy
- Where
- Pakistan
- Volunteers
- 70 people
- Sponsor
- University of Faisalabad
Dermatologic Disease, Vitiligo
Vitiligo Registry for Adults and Children in the UK
Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years…
- Trial name
- VIRTUAL-UK (NCT06218082)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Vitiligo, Nonsegmental Vitiligo
Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo
This randomized comparative study will evaluate the efficacy and safety of topical ruxolitinib 1.5% cream compared with topical tacrolimus 0.1% ointment, each combined with 308-nm excimer laser therapy, in patients aged 12 years…
- Trial name
- NCT07909668
- Testing
- Tacrolimus 0.1% ointment, Ruxolitinib 1.5% cream, 308-nm excimer laser
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Kafrelsheikh University
Psoriasis, Atopic Dermatitis
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12…
- Conditions
- Psoriasis, Atopic Dermatitis, Vitiligo, Alopecia Areata
- Trial name
- LANDSCAPE (NCT07336641)
- Testing
- Conventional Systemic Therapies, Biologic Therapies
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- Fondazione ISIDE
Vitiligo Vulgaris
Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo
The study is an on-line survey posted on survey monkey that addresses some demographic and environmental issues that could potentially relate to vitiligo vulgaris onset or disease exacerbation.
- Trial name
- NCT01401374
- Where
- United States
- Volunteers
- 3,258 people, healthy volunteers welcome
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Vitiligo - Macular Depigmentation, Tacrolimus
COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO
Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed
- Trial name
- NB-UVB (NCT06880042)
- Testing
- Tacrolimus, Calcipotriol
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dr ayesha wahid
Vitiligo
T Central Memory Cells in Early Localized Non-Segmental Vitiligo
Assessing the level of circulating TCMs (cluster of differentiation (CD) 8+, CD3+,C- chemokine receptor (CCR)7, cluster of differentiation 45 receptor (CD45R) cells) in early localized vitiligo cases prior to treatment and after…
- Trial name
- NCT05706636
- Testing
- oral mini pulse, Topical cream, targeted phototherapy
- Where
- Egypt
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Cairo University
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie
Vitiligo, Generalized
Catecholamines Level in Vitiligo Patients Before and After Excimer Light
Vitiligo is an acquired cutaneous disorder of pigmentation, with a 1-2% incidence worldwide, without predilection for sex or race.
- Trial name
- NCT04803461
- Testing
- serum and urinary catecholamines
- Volunteers
- 21 people
- Sponsor
- Assiut University
Atopic Dermatitis, Alopecia Areata
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice.
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- TARGET-DERM (NCT03661866)
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Dermatologic Disease, Vitiligo
Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo
OBJECTIVE: To investigate the efficacy of the cyclic on-off treatment compared to the conventional continuous excimer laser treatment. DESIGN: A randomized, controlled, split-body, non-inferiority study.
- Trial name
- NCT03047733
- Testing
- The XTRAC Excimer Laser System, Topical tacrolimus 0.1% ointment
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Ajou University School of Medicine
Vitiligo and Acne Vulgaris
Cutaneous JAK in Vitiligo and Acne Vulgaris.
The Janus kinase/signal transducer and activator of transcription (JAK-STAT) cytokine signaling pathway is an emerging area of interest in dermatology, and emerging evidence suggests that this pathway may play a crucial role in…
- Trial name
- NCT03185312
- Testing
- skin biopsy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Vitiligo
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.
- Trial name
- NCT06109649
- Testing
- Afamelanotide and NB-UVB Light, NB-UVB Light
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 200 people
- Sponsor
- Clinuvel, Inc.
Vitiligo
Contribution of Skin Color in Stabilization of Active Cases of Vitiligo by Narrow Band UVB
Vitiligo is a disease in which autoimmunity plays a major role. Multiple treatment options are available, of which narrow-band UVB is a cornerstone, acting through immunosuppression and repigmentation by stimulating reservoir…
- Trial name
- NCT04030988
- Testing
- Oral dexamethasone minipulse
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University